AstraZeneca (NYSE:AZN) announces positive data on PD-L1 inhibitor Imfinzi (durvalumab) at ASCO.
Results from
the Phase 2 Study 22 trial evaluating the combination of durvalumab and
anti-CTLA4 antibody tremelimumab in patients with advanced
hepatocellular carcinoma showed an acceptable safety profile and an
objective response rate (ORR) of 24% (300 mg of tremelimumab added to
durvalumab every four weeks). Median duration had not been reached at
data cutoff.
The Phase 3 CASPIAN study of durvalumab combined
with chemo in adults with extensive-stage small cell lung cancer in a
first-line setting met the primary endpoint
of overall survival (OS) with 27% less risk of death versus chemo alone
(previously reported). After median follow-up of more than two years,
the treatment effect was maintained, demonstrating 25% less risk of
death. Updated OS was 12.9 months versus 10.5 months for chemo. At month
24, 22% of patients receiving the combo were alive compared to 14.4% in
the chemo arm.
Shares up 4% premarket.
https://seekingalpha.com/news/3578641-astrazeneca-imfinzi-shows-positive-action-in-liver-and-lung-cancers
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.